Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Objective. Until recently, advanced medullary thyroid cancer (MTC) had few treatment options except surgery. The mTOR inhibitor everolimus has shown encouraging results in neuroendocrine tumors. As part of a prospective phase II study, we analyzed the safety and efficacy of everolimus in advanced MT...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Endocrinol
Main Authors: Schneider, T. C., de Wit, D., Links, T. P., van Erp, N. P., van der Hoeven, J. J. M., Gelderblom, H., van Wezel, T., van Eijk, R., Morreau, H., Guchelaar, H. J., Kapiteijn, E.
Format: Artigo
Jezik:Inglês
Izdano: Hindawi Publishing Corporation 2015
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4532868/
https://ncbi.nlm.nih.gov/pubmed/26294908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/348124
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki